SCHEMBL3027522

SCHEMBL3027522

CCOC(=O)c1cc2cc(NC(=O)OC(C)(C)C)ccc2[nH]1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 8/20 0.72
MMP2 P08253 6/20 0.63
LEF1 Q9UJU2 1/20 0.60
KDM4E B2RXH2 4/20 0.60
ALDH1A1 P00352 3/20 0.60
HPGD P15428 3/20 0.60
RAB9A P51151 3/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
HSD17B10 Q99714 1/20 0.60
NPC1 O15118 2/20 0.56
LMNA P02545 2/20 0.56
HTT P42858 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
HRH3 Q9Y5N1 1/20 0.56
MEN1 O00255 1/20 0.52
GLA P06280 1/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52
KMT2A Q03164 1/20 0.52
ATM Q13315 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17414823 0.89 MMP13 (0.64) MMP13MMP2LEF1KDM4EALDH1A1
SCHEMBL6617416 0.88 LEF1 (0.74) MMP13MMP2LEF1KDM4EALDH1A1
SCHEMBL7833243 0.86 LEF1 (0.55) MMP13MMP2LEF1KDM4EALDH1A1
SCHEMBL8204370 0.85 MMP13 (0.83) MMP13MMP2KDM4EALDH1A1HPGD
SCHEMBL8209912 0.85 MMP13 (0.83) MMP13MMP2KDM4EALDH1A1HPGD
SCHEMBL28291191 0.84 MMP13 (0.58) MMP13MMP2LEF1KDM4EALDH1A1
SCHEMBL28291196 0.84 MMP13 (0.58) MMP13MMP2LEF1KDM4EALDH1A1
SCHEMBL3030225 0.84 LEF1 (0.60) MMP13MMP2LEF1KDM4EALDH1A1
SCHEMBL6514040 0.84 MMP13 (1.00) MMP13MMP2KDM4EALDH1A1HPGD
SCHEMBL8209921 0.84 MMP13 (0.81) MMP13MMP2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9758480-B2 1-(cycloalkyl-carbonyl)proline derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-09-12 US disclosed
US-9758480-B2 1-(cycloalkyl-carbonyl)proline derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-09-12 US disclosed
US-9718840-B2 Condensed 5-oxazolidinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-08-01 US disclosed
US-9718840-B2 Condensed 5-oxazolidinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-08-01 US disclosed
US-20170022218-A1 CONDENSED 5-OXAZOLIDINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-01-26 US disclosed
US-20170022218-A1 CONDENSED 5-OXAZOLIDINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-01-26 US disclosed
EP-3095786-A1 CONDENSED 5-OXAZOLIDINONE DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2016-11-23 EP disclosed
EP-3095786-A1 CONDENSED 5-OXAZOLIDINONE DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2016-11-23 EP disclosed
CN-106103453-A It is condensed 5 oxazolidinone derivatives 大日本住友制药株式会社 2016-11-09 CN disclosed
EP-2121667-B1 CHEMICAL LINKERS WITH SINGLE AMINO ACIDS AND CONJUGATES THEREOF SQUIBB & SONS LLC (US) 2016-06-08 EP disclosed
US-20100145036-A1 CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF MEDAREX, INC. (US) 2010-06-10 US disclosed
US-20100145036-A1 CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF MEDAREX, INC. (US) 2010-06-10 US disclosed
US-20100113476-A1 CHEMICAL LINKERS WITH SINGLE AMINO ACIDS AND CONJUGATES THEREOF E. R. SQUIBB & SONS, L.L.C. 2010-05-06 US disclosed
US-20100113476-A1 CHEMICAL LINKERS WITH SINGLE AMINO ACIDS AND CONJUGATES THEREOF E. R. SQUIBB & SONS, L.L.C. 2010-05-06 US disclosed
EP-2166856-A1 CHEMICAL COMPOUNDS GlaxoSmithKline LLC (US) 2010-03-31 EP disclosed
WO-2008154271-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-18 WO disclosed
WO-2008103693-A2 CHEMICAL LINKERS WITH SINGLE AMINO ACIDS AND CONJUGATES THEREOF MEDAREX, INC. (US) 2008-08-28 WO disclosed
WO-2008083312-A2 CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF MEDAREX, INC. (US) 2008-07-10 WO disclosed
WO-2007038658-A2 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE MEDAREX, INC. (US) 2007-04-05 WO disclosed
US-5843937-A DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents PANORAMA RESEARCH, INC. (US) 1998-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113476-A1 CHEMICAL LINKERS WITH SINGLE AMINO ACIDS AND CONJUGATES THEREOF DNPEP, ANTXR2, CLSPN MMP13 3531/4885MMP2 2699/4885LEF1 4834/4885
US-20170022218-A1 CONDENSED 5-OXAZOLIDINONE DERIVATIVE F2, SERPINC1, F12 MMP13 1174/4885MMP2 1456/4885LEF1 1502/4885
US-20100145036-A1 CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF XIAP, ADAM8, CLSPN MMP13 610/4885MMP2 222/4885LEF1 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.